RxDoctor Payments Data

Brittany Simpson

Family · Seymour, TNNPI 1063877850

Payments from drug & device makers

$7,997in general payments, 2019–2025

Across 492 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$851
  • Xeris Pharmaceuticals, Inc.$733
  • Dexcom, Inc.$603
  • Insulet Corporation$576
  • Bayer$563
  • plus $3K from 44 others

What the payments were for

  • Food & beverage$7,92699%
  • Education$120%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,997 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$139,411
Medicare patients
265
Services billed
5,723

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide323$502,634
MounjaroTirzepatide295$406,053
JardianceEmpagliflozin285$330,162
Tresiba Flextouch U-200Insulin Degludec135$243,939
Xultophy 100-3.6Insulin Degludec/Liraglutide60$172,032
Fiasp FlextouchInsulin Aspart (Niacinamide)85$133,192
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/755$108,090
Soliqua 100-33Insulin Glargine/Lixisenatide44$93,689
Tresiba Flextouch U-100Insulin Degludec91$79,694
TrulicityDulaglutide32$55,181
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog29$51,961
Novolog FlexpenInsulin Aspart115$46,570
Synjardy XrEmpagliflozin/Metformin Hcl36$46,112
FiaspInsulin Aspart (Niacinamide)21$37,191
NovologInsulin Aspart75$33,001

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6, Fiasp, Novolog$1,272$744,858479 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi$851$478,272356 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Glyxambi, Trijardy Xr$58$431,286375 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$249$93,68944 claims
AstraZenecaFarxiga$74$25,56623 claims
AbbVieSynthroid$16$4,68168 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$31$4,054435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Seymour

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →